Towa Pharmaceutical Co., Ltd.
4553.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥65 | ¥65 | ¥66 | ¥70 |
| % Growth | 0.3% | -1.1% | -6.4% | – |
| Cost of Goods Sold | ¥42 | ¥41 | ¥42 | ¥45 |
| Gross Profit | ¥24 | ¥24 | ¥24 | ¥26 |
| % Margin | 36% | 36.3% | 36.4% | 36.7% |
| R&D Expenses | ¥0 | ¥0 | ¥4 | ¥5 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥18 | ¥18 | ¥19 | ¥12 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | -¥4 | ¥0 |
| Operating Expenses | ¥18 | ¥18 | ¥19 | ¥18 |
| Operating Income | ¥5 | ¥5 | ¥5 | ¥8 |
| % Margin | 8% | 8% | 7% | 11.5% |
| Other Income/Exp. Net | ¥3 | -¥1 | -¥0 | ¥3 |
| Pre-Tax Income | ¥8 | ¥4 | ¥4 | ¥12 |
| Tax Expense | ¥2 | ¥1 | ¥0 | ¥3 |
| Net Income | ¥6 | ¥3 | ¥4 | ¥8 |
| % Margin | 8.7% | 3.9% | 6.6% | 11.5% |
| EPS | 115.81 | 51.05 | 88.61 | 163.92 |
| % Growth | 126.9% | -42.4% | -45.9% | – |
| EPS Diluted | 115.81 | 51.05 | 88.61 | 163.92 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥1 | ¥1 | ¥0 | ¥0 |
| Depreciation & Amortization | ¥6 | ¥5 | ¥5 | ¥5 |
| EBITDA | ¥14 | ¥10 | ¥9 | ¥17 |
| % Margin | 21.8% | 16% | 14.2% | 24.3% |